Author

Lingzhi Hong

The University of Texas MD Anderson Cancer CenterORCID 0000-0001-6553-3279Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:statistical model· 2 Approach:deep learning· 1 Assay:imaging· 1 Assay:proteomics· 1

Frequent Co-Authors

Jianjun ZhangiD· 2 shared John Victor HeymachiD· 2 shared Alejandra SerranoiD· 1 shared Alexa Halliday· 1 shared Alexandre ReubeniD· 1 shared Amanda MontoyaiD· 1 shared Anika PateliD· 1 shared Bingnan ZhangiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Jianjun ZhangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 7, 2026

DLL3 expression predicts response and long-term outcome in small cell lung cancer patients treated with tarlatamab

Bingnan Zhang, Lingzhi Hong, Kaiwen Wang…·Lauren A. Byers

This study shows DLL3 expression level predicts response and long-term survival in SCLC patients treated with tarlatamab.

DOI 10.64898/2026.09.03.749238

𝕏 PostBluesky

ImmunologybioRxivPreprintAug 4, 2026

HER2 mutation-derived neoantigens in NSCLC as actionable targets for TCR therapy

Amanda Montoya, Hui Nie, Peixin Jiang…·Alexandre Reuben

The paper identifies TCRs targeting HER2 mutations in NSCLC, showing they recognize mutant epitopes and maintain cytotoxic activity, offering a potential immunotherapy strategy.

DOI 10.64898/2026.07.30.741830

humanproteomics

𝕏 PostBluesky